⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 1, 2024Asian Pacific Journal of Cancer PreventionOpen Access

Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial

Manar Hamed Ahmed Shaaban Mohamed Elbaiomy Ahmed Eltantawy Abdel-Hady El-Gilany Abdel-Fattah Sameh Shamaa

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Assessment of CBR, PFS, QOL and toxicity profile of palbociclib and ribociclib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shaaban et al. (2024) studied this question.

synapsesocial.com/papers/68e59d93b6db6435875384e8 https://doi.org/10.31557/apjcp.2024.25.9.3039

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1214P Comparing ribociclib versus palbociclib as a second-line treatment in combination with fulvestrant in metastatic breast cancer: A randomised clinical trial2024
2223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study2024 · 2 citations
3The analysis of prescribing CDK4/6 inhibitors for patients with breast cancer in real clinical practice.2024 · 2 citations
4A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort2025 · 2 citations
5Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer2024 · 9 citations